Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant ⛦to add to its current lineup of Ozempic and Wegovy.

The Danish drugmaker's stock was down 17% Friday morning after it had already been trending lower 澳洲幸运5官方开奖结果体彩网:since September, when 澳洲幸运5官方开奖结果体彩网:sales slowed slightly and concerns started to grow about the 澳洲幸运5官方开奖结果体彩网:increasing competition in the 澳洲幸运5官方开奖结果体彩网:weight loss drug market.

New Drug Led to 22.7% Weight Loss

Novo Nordisk said Friday that in the study of just over 3,400 patients, its new injectable weight loss drug CagriSema met its primary goal, with an average weight loss of 22.7% of a patient's body weight.

That compared to 11.8% and 16.1% of body weight lost by th♒e patients who took doses of just one of the two drugs that make up CagriSema, cagrilintide and semaglutide — the latter of which is the active ingredient in Ozempic and Wegovy.

The ingredients in the drug are designed to mimic chemicals released in the body after people eat, helping people feel full for longer, making it easier to reduce how 🔯muꩲch they eat.

The 22.7% average mark fell short of Novo Nordisk's goal reported last month by Bloomberg of 25% weight loss. Novo Nordisk said about 40% of people taking CagriSema reached the 25% mark.

Juܫst 57% of CagriSema patients reached the highest dosage level of the drug available during the trial, compared to 82.5% and 70.2% of the cagrilintide and semaglutide patients, respect𒁏ively, who took the highest dose of those drugs.

Novo Nordisk's U.S. shares were down 19.5% in premarket trading, poised to open at their lowest point since August 2023, after entering the day roughly flat this year. Shares of weight loss rival Eli Lilly (LLY) rose 7% following the trial results.